Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Hairy Cell 1

Interventions

Specimen Handling 69Magnetic Resonance Spectroscopy 52Biopsy 42pembrolizumab 26Carboplatin 26Cyclophosphamide 25Radiation 24Radiotherapy 23Nivolumab 23Cisplatin 21Paclitaxel 20olaparib 18Etoposide 18Doxorubicin 18Vincristine 17Dexamethasone 17X-Rays 16Immunoglobulin G 15Disulfides 15Cytarabine 15Taxes 14Prednisone 14Platinum 14Leucovorin 14Bevacizumab 141,2-diaminocyclohexaneplatinum II citrate 14durvalumab 13Radiotherapy, Intensity-Modulated 12Ipilimumab 12atezolizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Famotidine × 30 days × Clear all
NCT03805932 2026-05-19

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
18 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡